EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study

Yin Pan, Meichen Li, Mingjie Yu, Jing Chen, Hui Yu, Kaijing Liu, Likun Chen

Translational Oncology · 2025-11 · 61 · 102500

DOI: 10.1016/j.tranon.2025.102500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2025-11. Verfasst von Yin Pan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cente…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Third-generation EGFR tyrosine kinase inhibitors (TKIs) have improved outcomes in EGFR-mutant non-small cell lung cancer (NSCLC), but resistance occurs, especially in patients with Brain metastases (BMs). Antiangiogenic therapy may enhance CNS drug delivery and EGFR-TKI efficacy​. We evaluated the efficacy of high-dose furmonertinib plus bevacizumab in patients with BMs after third-generation EGFR-TKI failure. METHODS: We conducted a single-center retrospective study in EGFR-mutant NSCLC patients with BMs (leptomeningeal and/or parenchymal) who had progressed after ≥1 third-generation EGFR-TKI. Patients received furmonertinib 160 mg daily plus bevacizumab 7.5 mg/kg every 3 weeks until progression or unacceptable toxicity. Primary endpoints were intracranial and overall progression-free survival (iPFS, PFS); secondary endpoints were intracranial and systemic objective response rates (iORR, ORR) and safety. RESULTS: Among the 78 enrolled patients (median follow-up: 11.8 months), median iPFS and PFS were 7.2 months (95 % CI: 5.6-10.5) and 5.85 months (95 % CI: 4.6-7.4), respectively. The iORR was 37.1 %, and ORR was 28.6 %. OS data remain immature at the time of analysis. In patients with both parenchymal and leptomeningeal metastases (n = 47), median iPFS was 7.63 months (95 % CI: 5.0-10.8), and median PFS was 5.7 months (95 % CI: 4.5-10.0); iORR and ORR were 40.5 % and 34.2 %, respectively. In the parenchymal-only subgroup (n = 31), median iPFS and PFS were 7.20 months (95 % CI: 5.5-NR) and 6.4 months (95 % CI: 4.4-11.3), iORR and ORR were 32 % and 20 %. In multivariate analysis, EGFR exon 19 deletion was independently associated with prolonged iPFS (HR = 0.32, P = 0.011) and PFS (HR = 0.47, P = 0.047). CNS radiotherapy administered during treatment also emerged as an independent prognostic factor for both iPFS (HR = 0.34, P = 0.022) and PFS (HR = 0.40, P = 0.018). CONCLUSION: In this retrospective study, high-dose furmonertinib combined with bevacizumab demonstrated favorable intracranial and systemic activity with an acceptable safety profile in EGFR-mutant NSCLC patients with CNS metastases after resistance to third-generation EGFR-TKIs. These findings provide preliminary evidence supporting the potential clinical benefit of this chemotherapy-sparing strategy. Importantly, these findings warrant further validation in biomarker-stratified prospective trials to guide patient selection and optimize treatment outcomes.

Schlagwörter

Stichwörter der Autor:innen

Brain MetastasesEGFR mutationEGFR-TKI resistanceFurmonertinib

Autor:innen und Institutionen

  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.
  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China. Electronic address: chenlk…

Zitieren

APA

Pan, Y., Li, M., Yu, M., Chen, J., Yu, H., Liu, K., & Chen, L. (2025). High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study. Translational Oncology, 61, 102500. https://doi.org/10.1016/j.tranon.2025.102500

Vancouver

Pan Y, Li M, Yu M, Chen J, Yu H, Liu K, et al. High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study. Translational Oncology. 2025;61:102500. doi:10.1016/j.tranon.2025.102500

BibTeX
@article{Pan2025,
  author = {Pan, Yin and Li, Meichen and Yu, Mingjie and Chen, Jing and Yu, Hui and Liu, Kaijing and Chen, Likun},
  title = {High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study},
  journal = {Translational Oncology},
  year = {2025},
  volume = {61},
  pages = {102500},
  doi = {10.1016/j.tranon.2025.102500}
}
Kostenlos starten →